STOCK TITAN

CytoDyn (CYDY) Stock News

CYDY OTC

CytoDyn Inc. reports developments for leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor. The company is a clinical-stage oncology issuer focused on CCR5 biology in difficult-to-treat cancers, including metastatic triple-negative breast cancer and metastatic colorectal cancer.

Recurring news includes clinical and translational data presentations, Phase 2 colorectal cancer study updates, expanded access activity for triple-negative breast cancer, and preclinical work in glioblastoma. Company updates also cover financing actions used to support leronlimab development and corporate webcasts addressing scientific, operational, clinical, and financial progress.

Rhea-AI Summary

CytoDyn (CYDY) appointed Lauren Wilcoxen, Ph.D., as Chief Operating Officer and Head of Regulatory Affairs, effective November 20, 2026.

Wilcoxen has advised CytoDyn as a consultant over the past year, including on its Phase 2 CLOVER study evaluating leronlimab in metastatic colorectal cancer. She most recently served as Senior Vice President of Regulatory Affairs at Xilio Therapeutics. CytoDyn expects her to help guide CLOVER through Phase 2 completion and shape the next stages of leronlimab’s regulatory strategy. Wilcoxen identified working with the FDA to define a regulatory strategy for continued clinical development as a priority.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.20%
Tags
none
-
Rhea-AI Summary

CytoDyn (CYDY) completed an additional $5 million private investment to support clinical development of leronlimab in colorectal cancer and other solid tumors.

An anonymous existing investor purchased common shares at $0.24 per share, with no accompanying warrants, generating total proceeds of $5 million. CytoDyn plans to use the funding to advance its colorectal cancer program, building on emerging findings from the CLOVER study, and explore earlier treatment lines and other oncology indications, including triple-negative breast cancer, pancreatic cancer and glioblastoma.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.02%
Tags
none
-
Rhea-AI Summary

CytoDyn (OTCQB: CYDY) announced plans to evaluate leronlimab in two new metastatic triple-negative breast cancer regimens within QLHC’s PRE-I-SPY platform.

The Phase 1-1b studies will primarily assess safety and tolerability, alongside preliminary clinical activity and exploratory biomarkers. PRE5 will combine leronlimab with Merck’s pembrolizumab and sacituzumab; PRE7 will combine it with Akeso’s penpulimab, gemcitabine and carboplatin. CytoDyn expects PRE5 enrollment in the first quarter of 2027; PRE7 enrollment is likely in the second or third quarter of 2027. PRE5 will primarily enroll first- or second-line patients, while PRE7 will focus on second-line patients. Both will include patients with PD-L1 combined positive scores below 10, a measure of biomarker expression. QLHC sponsors the platform, and CytoDyn will provide leronlimab.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.42%
Tags
none
Rhea-AI Summary

CytoDyn (CYDY) presented updated Phase 2 CLOVER data on leronlimab in metastatic colorectal cancer at ESMO on October 25, 2026. The ongoing study enrolled 66 patients across seven sites and evaluates leronlimab with trifluridine/tipiracil plus bevacizumab.

CCR5 expression was detected in 91/91 evaluable archival tumor samples from pre-screened patients. Among 28 patients with baseline and Week 2 results, circulating tumor DNA, or ctDNA, fell a median 86% at Week 2. The combination produced greater reductions in molecular residual disease than trifluridine/tipiracil plus bevacizumab at 0–4 weeks (p=0.0005) and 0–8 weeks (p=0.0006), and deeper reductions than trifluridine/tipiracil alone at both intervals. Among 32 patients with available safety data, no leronlimab-related adverse events caused discontinuation or exceeded Grade 2; no leronlimab-related dose-limiting toxicities were observed.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.00%
Tags
none
-
Rhea-AI Summary

CytoDyn (CYDY) appointed Robert E. Hoffman as Chief Executive Officer, effective October 20, 2026, replacing Dr. Jacob Lalezari.

Lalezari will remain as Head of Research and Translational Sciences, focusing on identifying and advancing new opportunities for leronlimab in solid-tumor oncology. The board appointed Hoffman in consultation with Lalezari, who supports the transition. Hoffman joined CytoDyn as Chief Financial Officer in May 2025. The company said the transition comes as it prepares for its next phase of clinical development, with a focus on its oncology pipeline, regulatory milestones and potential partnerships.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.04%
Tags
none
-
News
Rhea-AI Summary

CytoDyn (CYDY) will host an investor webcast on October 19, 2026, to provide a corporate and clinical update. The livestream begins at 1 p.m. PT and will cover scientific, clinical, operational and financial progress, calendar 2026 priorities and upcoming milestones.

CEO Jacob P. Lalezari, CFO Robert E. Hoffman and City of Hope physician Pashtoon M. Kasi will participate. Natera’s Reny Aniline will discuss the recently announced Natera-CytoDyn collaboration and early ctDNA observations in the CLOVER study. A live question-and-answer session is planned, and a replay will be available for approximately 30 days on CytoDyn’s investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.70%
Tags
conferences
Rhea-AI Summary

CytoDyn (CYDY) will present updated Phase 2 CLOVER study data at the ESMO Congress on October 25, 2026, in Madrid, Spain. The ongoing study evaluates leronlimab combined with trifluridine/tipiracil (TAS-102) and bevacizumab in patients with previously treated metastatic colorectal cancer, meaning cancer that has spread.

Benjamin Weinberg, M.D., Associate Professor at Georgetown University, will present poster 820P from 12:00–12:45 p.m. CET in the Poster Area, Hall 5, at IFEMA Madrid. The congress runs October 23–27, 2026. CytoDyn plans to make the poster available in its website’s Publications & Posters section shortly after the presentation. The announcement schedules the updated findings but provides no clinical results.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.80%
Tags
-
Rhea-AI Summary

CytoDyn (OTCQB: CYDY) closed a $16.5 million financing, with Paulson Investment Company as placement agent, to support continued development of its CCR5-targeting monoclonal antibody leronlimab in oncology indications such as TNBC and mCRC. According to CytoDyn, this capital is expected to fund operations into the second half of 2027.

Net proceeds are planned for ongoing and planned clinical trials, regulatory activities, data analysis, manufacturing readiness, regulatory and compliance infrastructure, and general working capital, aligning resources with the company’s clinical execution and strategic priorities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.22%
Tags
none
-
Rhea-AI Summary

CytoDyn (OTCQB: CYDY) announced dosing of the first patient in SALIENT-AD, a Phase 2a, open-label, proof-of-concept study of leronlimab in biomarker-confirmed early-stage Alzheimer’s disease patients over 50, conducted with Weill Cornell Medicine.

The 12-week trial (10–20 patients) will test weekly subcutaneous leronlimab, focusing on brain inflammation and microglial activation via PET imaging, plus safety, cognition, blood biomarkers, and MRI-based blood-brain barrier measures.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
partnership
Rhea-AI Summary

Natera (NASDAQ:NTRA) and CytoDyn (OTCQB:CYDY) announced a strategic collaboration on June 4, 2026 to support leronlimab development in metastatic colorectal cancer (mCRC).

Natera will use its personalized MRD assay Signatera and a large real-world molecular oncology dataset to analyze ctDNA dynamics in samples from CytoDyn’s CLOVER Phase 2 mCRC study.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.55%
Tags
partnership

FAQ

What is the current stock price of CytoDyn (CYDY)?

CytoDyn (CYDY) last closed at $0.2220.

What is the market cap of CytoDyn (CYDY)?

The market cap of CytoDyn (CYDY) is approximately $326.2M.